Introduction {#section1-1178636119889629}
============

Multidrug resistance of pathogenic microorganisms, for example, bacteria, is a global noteworthy concerning issue. Pathogens resistant to 3 or more antibiotics are called multidrug resistant (MDR).^[@bibr1-1178636119889629],[@bibr2-1178636119889629]^ Infections by MDR pathogens are difficult to treat and have been associated with worse disease outcomes, and hence, impose a major threat.^[@bibr3-1178636119889629],[@bibr4-1178636119889629]^ Recent studies suggest that antibiotic-resistant bacteria can be more virulent than their antimicrobial-susceptible counterparts.^[@bibr5-1178636119889629]^ The antimicrobial resistance (AMR) in bacteria is emerging globally unprecedentedly and the resistant pattern differs based on geographical locations.^[@bibr6-1178636119889629]^ There are a plethora of means by which humans have inadvertently accelerated the evolution of bacterial resistance. The over prescription of antibiotics by doctors for symptoms that in many cases may not be caused, unnecessary use of antimicrobials in agriculture and aquaculture and their dissemination in the environment are contributing to AMR worldwide. Recently, global warming and climate change are also supposed to contribute to AMR.^[@bibr7-1178636119889629],[@bibr8-1178636119889629]^ Furthermore, in developing countries, such as Bangladesh, self-medication with antibiotics due to their easy availability in the pharmacy, selling pill-by-pill, misuse and abuse of antibiotics, and not fulfilling the prescribed antibiotic regimens once the patient feels better are the reasons of increasing AMR.^[@bibr2-1178636119889629],[@bibr9-1178636119889629][@bibr10-1178636119889629]-[@bibr11-1178636119889629]^ Emerging AMR in developing countries is not necessarily regionally confined, as today's globalized world allows for resistant bacteria as well as people to travel around the world.^[@bibr12-1178636119889629]^ Therefore, molecular elucidation of multidrug resistance in pathogen of different geographical regions is required due to variance in antibiotic intake, agricultural use, and climate change in different areas of the world.

Susceptible bacteria can acquire resistance to an antimicrobial agent through mutation, degradation, or changing the structure of antibiotic, efflux pump, and conjugation and/or transformation of the plasmid.^[@bibr2-1178636119889629],[@bibr13-1178636119889629],[@bibr14-1178636119889629]^ Efflux pump proteins, found in both Gram-positive and Gram-negative bacteria as well as in eukaryotic microorganisms,^[@bibr15-1178636119889629]^ are transporter proteins involved in the extrusion of toxic substrates from within cells into the external environment. The impact of efflux mechanisms on AMR is large, and antibiotics can act as inducers and repressors of the expression of some efflux pump proteins.^[@bibr16-1178636119889629]^ AcrAB-TolC, one of the efflux pumps, constitutively expressed in *Escherichia coli*, is composed of the outer membrane protein TolC, the inner membrane transporter AcrB, and the periplasmic adaptor protein AcrA.^[@bibr14-1178636119889629],[@bibr17-1178636119889629]^ Overexpression of the AcrAB-TolC efflux pump is an intrinsic mechanism of multidrug resistance in Gram-negative bacteria.^[@bibr14-1178636119889629],[@bibr17-1178636119889629],[@bibr18-1178636119889629]^ It can be due to the mutation in *AcrR* gene which is the repressor of the *AcrAB* operon system.^[@bibr19-1178636119889629]^ Substrate profiles of the *E. coli* housekeeping efflux system AcrAB-TolC include chloramphenicol, fluoroquinolone, tetracycline, novobiocin, fusidic acid, nalidixic acid and β-lactam antibiotics, dyes, detergents, and most lipophilic antibiotics.^[@bibr16-1178636119889629],[@bibr20-1178636119889629]^ The expression of AcrAB is regulated by the repressor AcrR, encoded by *AcrR.*^[@bibr19-1178636119889629]^ It has been shown that a C133T transversion resulting in arginine to cysteine substitution at codon 45 of *AcrR* is responsible for overexpression of the AcrAB efflux system and results in AMR.^[@bibr21-1178636119889629]^ Therefore, the antibiotic therapy can be made effective if (1) efflux pumps are inhibited, (2) the expression of efflux pumps is downregulated, or (3) the antibiotics are structurally redesigned, so that they are no longer suitable efflux substrates.^[@bibr22-1178636119889629]^ One of the rational approaches toward confronting efflux of clinically relevant antibiotics is to discover or design potent efflux pump inhibitors. A number of known compounds have been reported as efflux pump inhibitors such as verapamil, biricodar, moxifloxacin, and omeprazole.^[@bibr14-1178636119889629],[@bibr19-1178636119889629],[@bibr23-1178636119889629],[@bibr24-1178636119889629]^ Although several reports show the inhibitory effects of omeprazole on bacterial efflux pumps,^[@bibr23-1178636119889629],[@bibr25-1178636119889629],[@bibr26-1178636119889629]^ very few studies have been done to show its inhibitory effects on efflux pumps of *E. coli*.

Urinary tract infection (UTI) is recognized as the second most common infection in community practice.^[@bibr27-1178636119889629]^ Globally, about 150 million people are diagnosed with UTI each year, costing the global economy in excess of US\$6 billion.^[@bibr28-1178636119889629]^ Recently, it is reported that about 60% of UTIs are caused by *E. coli* and \~90% of these *E. coli* isolates are MDR in the North-East region of Bangladesh.^[@bibr2-1178636119889629]^ In 2000, only 7.1% MDR *E. coli* were reported in patients of the United States,^[@bibr29-1178636119889629]^ whereas in 2011, 77% MDR *E. coli* were reported in UTI patients in Iran,^[@bibr30-1178636119889629]^ indicating rapid and threatening emergence of antibiotic resistance in *E. coli* causing UTI. Although about 90% of the *E. coli* isolates causing UTI are MDR,^[@bibr2-1178636119889629]^ the molecular reasons of multidrug resistance in these MDR *E. coli* are not yet elucidated. In this study, the efflux pump system has been assayed using omeprazole and ethidium bromide (EtBr). Because the sequence of *AcrAB-TolC* and mutation of *AcrR* in the *E. coli* isolates may differ due to the reasons aforementioned and contribute to AMR,^[@bibr2-1178636119889629],[@bibr6-1178636119889629][@bibr7-1178636119889629][@bibr8-1178636119889629][@bibr9-1178636119889629][@bibr10-1178636119889629]-[@bibr11-1178636119889629]^ the *AcrA, AcrB, TolC*, and *AcrR* genes have been isolated and sequenced. The present report shows that the omeprazole increases the susceptibility of MDR *E. coli* isolates against almost all the antibiotics being investigated, *AcrAB-TolC* are constitutive genes, and there is a correlation between antibiotic susceptibility and the mutation in *AcrR* in MDR *E. coli* isolates causing UTI in the North-East region of Bangladesh.

Materials and Methods {#section2-1178636119889629}
=====================

*E. coli* isolates and their maintenance {#section3-1178636119889629}
----------------------------------------

The MDR *E. coli* isolates were obtained from urine samples of UTI patients in North-East region of Bangladesh.^[@bibr2-1178636119889629]^ The pure culture of *E. coli* isolates was routinely subcultured on nutrient agar (NA; 0.5% peptone, 0.15% yeast extract, 0.15% beef extract, 0.5% NaCl, 1.5% agar; pH 7.0) and preserved at −20°C in nutrient broth (NB; 0.5% peptone, 0.15% yeast extract, 0.15% beef extract, 0.5% NaCl; pH 7.0) with 15% glycerol.

Antibiogram and efflux assay of antibiotics with proton pump inhibitor {#section4-1178636119889629}
----------------------------------------------------------------------

The presence of efflux pumps in antibiotic-resistant *E. coli* isolates was screened by the increase in antibiotic susceptibility in the presence of omeprazole, an H^+^/K^+^ proton pump inhibitor.^[@bibr14-1178636119889629],[@bibr23-1178636119889629],[@bibr25-1178636119889629],[@bibr26-1178636119889629],[@bibr31-1178636119889629]^ The antibiotic disks of amoxicillin (AMX), azithromycin (AZM), ciprofloxacin (CIP), cefixime (CFM), ceftriaxone (CTR), gentamicin (GEN), and sulfamethoxazole (SXT) were added to the surface of culture on Mueller Hinton Agar (MHA; beef extract 0.2%, acid hydrolysate of casein 1.75%, starch 0.15%, Agar 1.7%; pH 7.3) of each plate supplemented with or without 100 µg/mL omeprazole. The zone of inhibition produced by the antibiotic disks was compared with the standard clear zone diameters of these disks against Enterobacteriaceae stated in the guidelines of Clinical and Laboratory Standards Institute (CLSI).^[@bibr32-1178636119889629]^

The minimum inhibitory concentration (MIC) of each of the antibiotics aforementioned was determined in the presence or absence of 100 µg/mL omeprazole by the broth dilution method as described previously.^[@bibr33-1178636119889629]^

EtBr efflux assay of *E. coli* isolates {#section5-1178636119889629}
---------------------------------------

Efflux of EtBr was tested by the EtBr cartwheel procedure.^[@bibr34-1178636119889629]^ Bacterial isolates were cultured overnight with NB (0.5% peptone, 0.15% yeast extract, 0.15% beef extract, 0.5% NaCl; pH 7.0) in a shaker and the cell concentration was adjusted to 0.5 of a McFarland standard^[@bibr35-1178636119889629]^ in the following day. The NA plates were divided by radial lines, forming a cartwheel pattern. The bacterial cultures were then swabbed (using sterilized cotton swab) on NA plates containing 1.5 µg/mL EtBr in the presence or absence of 100 µg/mL omeprazole, and incubated at 37°C for 16 h. The culture on the NA plates was examined under a UV transilluminator.

Isolation and sequencing of *AcrA*, *AcrB*, and *TolC* genes {#section6-1178636119889629}
------------------------------------------------------------

Chromosomal DNA was extracted from overnight culture of *E. coli* isolates in NB with Favorgen genomic DNA purification kit in accordance with the manufacturer's instruction (Favorgen Biotech. Corp., Taiwan). *AcrA, AcrB*, and *TolC* genes were amplified by polymerase chain reaction (PCR) using gene-specific primers ([Table 1](#table1-1178636119889629){ref-type="table"}). The PCR reaction mixture for each gene was prepared in a total volume of 25 µL consisting of 12.5 µL of master mixture (GoTaq® Green Master Mix; Promega, USA), 1.5 µL of 50 µM forward and reverse primers (IDT, Singapore), 2.5 µL of genomic DNA (⩽250 ng) and 7 µL of sterile deionized water. Polymerase chain reaction conditions for amplification of *AcrA* were programmed to 1 cycle at 94°C for 1 min; 35 cycles at 94°C for 30 s, at 55°C for 45 s, and at 72°C for 2 min; and 1 cycle at 72°C for 10 min. For amplification of *AcrB* and *TolC*, the PCR cycle was programmed to 1 cycle at 94°C for 1 min; 35 cycles at 94°C for 30 s, at 65°C for 45 s, and 72°C for 2 min; and 1 cycle at 72°C for 10 min. The PCR products were purified and sequenced as described previously.^[@bibr37-1178636119889629]^ The sequence was analyzed by a free computer program BioEdit 7.2.5. The similarities of the sequences were searched by BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) search program, and nucleotide sequences were submitted to DNA Data Bank of Japan (DDBJ).

###### 

Primers used for the detection of *AcrAB-TolC* efflux pump genes and ARMS PCR for *AcrR.*

![](10.1177_1178636119889629-table1)

  Primer      Sequence (5′→3′)                       Reference
  ----------- -------------------------------------- ------------------------------
  *AcrB*-FP   GAAAGGCCAACAGCTTAAC                    ^[@bibr36-1178636119889629]^
  *AcrB*-RP   GAGCTGGAGTCAGGATCAAC                   
  *TolC-*FP   TGCTCCCCATTCTTATCGGC                   
  *TolC-*RP   GCTCTTGCTTGGCGTTGTAC                   
  *AcrA*-FP   CAATTTGAAATCGGACACTCG                  This study
  *AcrA*-RP   GGCATGTCTTAACGGCTCCT                   
  *AcrR* FP   CGACCGCCAGAGGCGTAAACCC                 
  Inner FP    CGCTGGGCGAGATTGCAAAAGCAGCTGGCGTTTCGT   
  *AcrR* RP   ACGAAGCGTGGGGCACAGGAGA                 

Abbreviation: ARMS PCR, amplification refractory mutation system polymerase chain reaction.

Detection of mutation in *AcrR* by ARMS PCR {#section7-1178636119889629}
-------------------------------------------

Tri primer amplification refractory mutation system polymerase chain reaction (ARMS PCR)^[@bibr38-1178636119889629]^ was done by using 1 set of gene-specific primer and 1 mutation-specific primer ([Table 1](#table1-1178636119889629){ref-type="table"}) for determining the mutation in *AcrR* gene. The amplification efficiency of each pair of primers: (1) *AcrR* FP and *AcrR* RP and (2) inner FP and *AcrR* RP was tested. The PCR reaction mixtures were prepared as aforementioned concentration. The PCR condition was programmed to 1 cycle at 94°C for 1 min; 35 cycles at 94°C for 30 s, at 62°C for 45 s and at 72°C for 1 min; 1 cycle at 72°C for 10 min. For ARMS PCR, 40 µL reaction mixture consisting of 20 µL of master mixture (GoTaq® Green Master Mix; Promega, USA), 1 µL of *AcrR* FP (1 µM), 1 µL of inner FP (1 µM) and 2 µL *AcrR* RP (2 µM; IDT, Singapore), 3.5 µL of genomic DNA (⩽250 ng), and 12.5 µL of sterile deionized water was prepared. The ARMS PCR was programmed to 1 cycle at 94°C for 2 min; 35 cycles at 94°C for 30 s, at 62°C for 30 s, and at 72°C for 1 min, and final extension at 72°C for 2 min.

The PCR amplicons were subjected to electrophoresis and visualized in 1% agarose. Polymerase chain reaction products were purified from agarose gel and sequenced as described previously.^[@bibr39-1178636119889629]^ The sequences were analyzed as aforementioned.

Results and Discussion {#section8-1178636119889629}
======================

About 90% of the *E. coli* isolates causing UTI in the North-East region of Bangladesh were reported as MDR, and the multidrug resistance in *E. coli* might be either plasmid or chromosomal DNA mediated or the both.^[@bibr2-1178636119889629],[@bibr13-1178636119889629]^ In this study, the efflux pump system has been discussed as one of the reasons for multidrug resistance in the MDR *E. coli* isolates causing UTIs and omeprazole may be an efflux pump inhibitor.

Antibiotic susceptibility in the presence of omeprazole {#section9-1178636119889629}
-------------------------------------------------------

The efflux systems play important role in antibiotic resistance in MDR bacteria,^[@bibr40-1178636119889629]^ and omeprazole is reported as an efflux pump inhibitor.^[@bibr23-1178636119889629],[@bibr31-1178636119889629]^ To investigate the presence of efflux pump, we randomly selected 18 MDR *E. coli* isolates causing UTI.^[@bibr2-1178636119889629]^ Their susceptibility to AMX, AZM, CFM, CIP, CTR, GEN, and SXT was assayed in the presence and absence of omeprazole ([Figure 1](#fig1-1178636119889629){ref-type="fig"} and [Table 2](#table2-1178636119889629){ref-type="table"}). In the presence of omeprazole, the diameter of zone of inhibition by at least 1 of the 7 antibiotics increased against all MDR *E. coli* isolates ([Table 2](#table2-1178636119889629){ref-type="table"}). The result indicated that the omeprazole, an efflux pump inhibitor,^[@bibr23-1178636119889629]^ increased the antibiotic susceptibility, supporting the notion of the presence of efflux pump in the MDR *E. coli* isolates. The percentage of the MDR *E. coli* isolates that showed efflux activity to AMX, AZM, CFM, CIP, CTR, and SXT was about 22, 44, 72, 66, 38, and 66, respectively. About 77% of the MDR *E. coli* isolates showed efflux activity against 3 or more antibiotics. This result further indicated that efflux activity might be one of the mechanisms of multidrug resistance.

![Representative antibiogram of *Escherichia coli* isolate 15 in the absence (A) and presence (B) of omeprazole, and *E. coli* ATCC 25922 in the absence of omeprazole (C).](10.1177_1178636119889629-fig1){#fig1-1178636119889629}

###### 

Increase in zone of inhibition of *Escherichia coli* isolates to different antibiotic disks in the presence of omeprazole.^[a](#table-fn3-1178636119889629){ref-type="table-fn"}^

![](10.1177_1178636119889629-table2)

  Isolates   AMX   AZM   CFM   CIP   CTR   GEN   SXT                                 
  ---------- ----- ----- ----- ----- ----- ----- ----- ---- ---- ---- ---- ---- ---- ----
  02         NZ    NZ    NZ    NZ    NZ    NZ    NZ    NZ   NZ   NZ   14   14   13   13
  06         NZ    NZ    16    22    16    20    22    26   20   27   18   25   16   21
  08         NZ    NZ    22    24    16    17    23    27   19   21   20   24   18   24
  11         NZ    NZ    14    20    NZ    22    NZ    22   NZ   22   14   20   16   19
  14         NZ    15    14    20    NZ    22    NZ    27   NZ   17   14   16   18   27
  15         NZ    NZ    9     15    NZ    19    10    31   NZ   29   18   18   NZ   25
  16         NZ    NZ    26    30    14    19    25    27   25   28   20   26   23   25
  17         NZ    NZ    22    25    NZ    NZ    NZ    25   NZ   NZ   14   16   22   26
  18         NZ    18    NZ    19    NZ    NZ    NZ    NZ   NZ   NZ   NZ   16   18   25
  19         NZ    NZ    18    22    NZ    NZ    30    32   24   26   14   17   21   27
  20         NZ    NZ    15    18    22    26    18    22   22   29   16   22   16   22
  22         NZ    NZ    22    26    18    22    NZ    19   25   27   34   41   12   15
  26         NZ    NZ    23    25    18    27    25    26   26   27   18   25   19   24
  27         NZ    NZ    20    22    NZ    NZ    NZ    16   NZ   NZ   18   27   NZ   NZ
  29         NZ    NZ    18    20    NZ    15    NZ    18   NZ   NZ   15   17   NZ   14
  30         NZ    22    17    19    NZ    18    NZ    17   24   25   14   16   17   25
  31         NZ    NZ    14    17    18    20    22    24   19   24   17   20   23   27
  32         NZ    16    19    21    NZ    19    NZ    NZ   NZ   22   15   18   11   15

Abbreviations: AMX, amoxicillin; AZM, azithromycin; C, absence of omeprazole; CFM, cefixime; CIP, ciprofloxacin; CTR, ceftriaxone; GEN, gentamicin; NZ, no zone of inhibition; O, presence of omeprazole; SXT, sulfamethoxazole.

⩾4 mm increase in zone of inhibition in the presence of omeprazole compared with that in the absence of omeprazole was considered as the increase in antibiotic susceptibility.

The efflux pump inhibition by omeprazole was further investigated through determining the MIC of each antibiotic against the *E. coli* isolates as well as the *E. coli* ATCC 25922. Omeprazole treatment reduced the MIC of almost all antibiotics being investigated for the MDR *E. coli* isolates by 2-fold to 8-fold ([Table 3](#table3-1178636119889629){ref-type="table"}). Minimum inhibitory concentration of the same antibiotic varied up to 2-fold based on different *E. coli* isolates. However, the MIC of the same antibiotic for the *E. coli* ATCC 25922 was at least 2-fold to 4-fold less than that found against the *E. coli* isolates treated with omeprazole. Nevertheless, the MIC of the *E. coli* ATCC did not further change in the presence of omeprazole. This result indicated the presence of active efflux pumps in the *E. coli* isolates but not in the *E. coli* ATCC 25922, which was susceptible to all the antibiotics being investigated ([Figure 1C](#fig1-1178636119889629){ref-type="fig"}). In addition, this result suggests that omeprazole can act as an efflux pump inhibitor in agreement with other studies.^[@bibr23-1178636119889629],[@bibr25-1178636119889629],[@bibr26-1178636119889629]^ Molecular docking shows that omeprazole has significant interaction to NorA, an efflux pump in *Staphylococcus aureus* with low binding energy.^[@bibr24-1178636119889629]^ However, further study is necessary to clarify which efflux pump(s) in *E. coli* isolates is inhibited by omeprazole.

###### 

MIC of MDR *Escherichia coli* isolates in the absence and presence of omeprazole.^[a](#table-fn5-1178636119889629){ref-type="table-fn"}^

![](10.1177_1178636119889629-table3)

  Antibiotics   MIC of antibiotics against *E. coli* isolates   MIC reduced in the presence of omeprazole (fold)   MIC of antibiotics against *E. coli* ATCC 25922 (µg/µL)   
  ------------- ----------------------------------------------- -------------------------------------------------- --------------------------------------------------------- --------
  AMX           4-8                                             2-4                                                2                                                         0.5
  AZM           4-8                                             1-2                                                4                                                         0.5
  CFM           2-4                                             0.25-0.5                                           8                                                         0.125
  CIP           4-8                                             0.5-1                                              8                                                         0.5
  CTR           2-4                                             0.5-1                                              4                                                         0.5
  GEN           1-2                                             0.125-0.25                                         8                                                         0.0625
  SXT           4-8                                             2-4                                                2                                                         2

Abbreviations: AMX, amoxicillin; AZM, azithromycin; CFM, cefixime; CIP, ciprofloxacin; CTR, ceftriaxone; GEN, gentamicin; MIC, minimum inhibitory concentration; MDR, multidrug resistant; SXT, sulfamethoxazole.

Every experiment was repeated at least 3 times.

The presence of efflux pump was further tested by using EtBr. In the absence of omeprazole, many of the MDR *E. coli* isolates grown in the media containing EtBr failed to produce the characteristic intense orange fluorescence, indicating the possible efflux of EtBr from the cell ([Figure 2A](#fig2-1178636119889629){ref-type="fig"} and [C](#fig2-1178636119889629){ref-type="fig"}). However, when these strains were grown in the presence of omeprazole, strong fluorescence was observed indicating possible inhibition of the efflux process by omeprazole ([Figure 2B](#fig2-1178636119889629){ref-type="fig"} and [D](#fig2-1178636119889629){ref-type="fig"}). In the presence of omeprazole, EtBr could not come out from more than 70% of the bacterial isolates, and therefore, retained in the cell. Consequently, strong fluorescence was observed under a UV transilluminator and the antibiotic susceptibility increased ([Table 4](#table4-1178636119889629){ref-type="table"}). This result supports the correlation between the efflux pump and the AMR of the *E. coli* isolates. The efflux system might be largely responsible for intrinsic resistance of some *E. coli* isolates to antibiotics.^[@bibr23-1178636119889629]^ Therefore, antibiotics combined with efflux system blockers may increase the susceptibility of bacteria to a given antibiotic to a clinical relevant level.^[@bibr41-1178636119889629],[@bibr42-1178636119889629]^ However, although a few bacterial isolates showed strong fluorescence under a UV transilluminator, they moderately increase susceptibility to antibiotics in the presence of omeprazole.

![Efflux of EtBr from some *Escherichia coli* isolates in the absence (A and C) and presence (B and D) of omeprazole.\
EtBr indicates ethidium bromide.](10.1177_1178636119889629-fig2){#fig2-1178636119889629}

###### 

Omeprazole-mediated efflux inhibition of EtBr and increase in antibiotic susceptibility.

![](10.1177_1178636119889629-table4)

  *Escherichia coli* isolates   Name of resistant antibiotics      Increase in antibiotic susceptibility in the presence of omeprazole   EtBr fluorescence in the presence of omeprazole
  ----------------------------- ---------------------------------- --------------------------------------------------------------------- -------------------------------------------------
  02                            CTR, CIP, AMX, CFM, AZM, NA, F     No                                                                    Moderate
  06                            AMX, NA, F                         Yes                                                                   Strong
  08                            AMX, NA, F                         Yes                                                                   Strong
  11                            CTR, CIP, NA, AMX, CFM, F          Yes                                                                   Strong
  14                            CTR, CIP, AMX, CFM, NA, F          Yes                                                                   Strong
  15                            CTR, CIP, AMX, CFM, AZM, SXT, NA   Yes                                                                   Strong
  16                            AMX, CFM, NA                       Moderate                                                              Strong
  17                            CTR, CIP, CFM, NA, AMX             Yes                                                                   Strong
  18                            CTR, CIP, AMX, NA, CFM, GEN, AZM   Moderate                                                              Strong
  19                            AMX, NA, CFM                       Yes                                                                   Strong
  20                            AMX, NA                            Yes                                                                   Strong
  22                            CIP, AMX, NA                       Moderate                                                              Strong
  26                            AMX, NA, F                         Yes                                                                   Strong
  27                            CTR, CIP, NA, AMX, CFM, SXT        Moderate                                                              Strong
  29                            CTR, CIP, AMX, NA, CFM, SXT, F     Moderate                                                              Strong
  30                            CIP, AMX, CFM, NA, F               Yes                                                                   Strong
  31                            AMX, NA, F                         Yes                                                                   Strong
  32                            CTR, CIP, AMX, CFM, NA             Moderate                                                              Moderate

Abbreviations: AMX, amoxicillin; AZM, azithromycin; CFM, cefixime; CIP, ciprofloxacin; CTR, ceftriaxone; EtBr, ethidium bromide; GEN, gentamicin; SXT, sulfamethoxazole.

Molecular detection and *in silico* characterization of *AcrA*, *AcrB*, and *TolC* genes in *E. coli* isolates {#section10-1178636119889629}
--------------------------------------------------------------------------------------------------------------

The association of the AcrAB-TolC efflux pump with antibiotic resistance is reported in bacteria.^[@bibr43-1178636119889629]^ As more than 70% of the *E. coli* isolates have been assayed to have the efflux pump, an attempt was made to isolate and identify *AcrA, AcrB*, and *TolC* genes in their chromosomal DNA. In the presence of omeprazole, the MDR *E. coli* isolates that showed increased susceptibility to antibiotics and those that showed no increased susceptibility were selected for molecular detection of *AcrA, AcrB*, and *TolC* through PCR and DNA sequencing. The presence of *AcrA, AcrB*, and *TolC* genes with the size of 1194, 761, and 1170 bp, respectively, were found in both groups of *E. coli* isolates ([Figure 3](#fig3-1178636119889629){ref-type="fig"}). The similarity search with the BLAST revealed that *AcrA, AcrB*, and *TolC* of *E. coli* isolates were 99%, 99%, and 95% identical, respectively, to those of *E. coli*. The nucleotide sequences of *AcrA, AcrB*, and *TolC* had been deposited to DDBJ under the accession number LC385717, LC385718, and LC271678, respectively. The amino acid sequences of AcrA, AcrB, and TolC were deduced by GENETYX-SV/RC version 7.0 program (Genetyx Corp., Japan) for further structural proteomics analysis. The physicochemical properties of these 3 deduced proteins investigated by ProtParam tools (<https://web.expasy.org/protparam/>) of the ExPASy server revealed that the theoretical pI of TolC is basic in nature and that of AcrA and AcrB is slightly acidic ([Table 5](#table5-1178636119889629){ref-type="table"}). The extinction coefficient that is necessary during protein purification is different for AcrA, AcrB, and TolC. AcrAB proteins are much stable than TolC, and their aliphatic index indicated them as thermostable proteins ([Table 5](#table5-1178636119889629){ref-type="table"}). The value of GRAVY (grand average of hydropathicity) calculated using the hydropathy value from Kyte and Doolittle^[@bibr44-1178636119889629]^ is low for AcrA and TolC, indicating the possibility of their better interaction with water than that of AcrB. The pI and the hydropathy values are important for subcellular localization of channel forming membrane proteins. Recently, the in situ structure and assembly of the AcrAB-TolC efflux pump have been reported.^[@bibr17-1178636119889629]^ Therefore, it will be interesting if molecular docking of omeprazole and other efflux pump inhibitors^[@bibr14-1178636119889629],[@bibr24-1178636119889629]^ is done to predict the inhibitor profiles of the AcrAB-TolC efflux pump.

![PCR products of *AcrA* (A), *AcrB* (B), and *TolC* (C) genes in 1% agarose gel.\
L indicates the DNA ladder; PCR, polymerase chain reaction. *Escherichia coli* isolate numbers are indicated above the image of the gel with PCR products shown by an arrow.](10.1177_1178636119889629-fig3){#fig3-1178636119889629}

###### 

Physicochemical properties of AcrA, AcrB, and TolC proteins of the *Escherichia coli* isolates.

![](10.1177_1178636119889629-table5)

  Parameters                                     Values                  
  ---------------------------------------------- ----------- ----------- -----------
  Molecular weight (Da)                          42,283.78   27,093.00   42,602.59
  Theoretical pI                                 6.06        5.54        10.05
  Extinction coefficients (M^−1^ cm^−1^)         0.447       0.275       1.205
  The estimated half-life (*E. coli*, in vivo)   \>10 h      3 min       \>10 h
  Instability index                              29.46       24.35       43.51
  Aliphatic index                                91.44       119.49      69.07
  Grand average of hydropathicity (GRAVY)        −0.266      0.690       −0.587

Abbreviation: aa, amino acids.

The AcrB and TolC are localized on inner and outer parts of the membrane, respectively, and AcrA protein performs as an adapter of AcrB-TolC on the periplasmic region.^[@bibr45-1178636119889629][@bibr46-1178636119889629]-[@bibr47-1178636119889629]^ Both AcrB and TolC comprise membrane domain as well as transmembrane region.^[@bibr48-1178636119889629],[@bibr49-1178636119889629]^ The similar result was found in this study by computational analysis of AcrA, AcrB, and TolC with Pfam (<https://pfam.xfam.org/>) and TMpred (<https://embnet.vital-it.ch/software/TMPRED_form.html>). Three transmembrane helices were predicted in AcrB, 1 in TolC but not in AcrA ([Table 6](#table6-1178636119889629){ref-type="table"}). Domain and transmembrane analyses indicate that AcrB is a member of integral membrane protein and cooperates with a fusion membrane protein AcrA and an outer membrane channel TolC. Two domains found by Pfam analysis may make the TolC unique as the outer membrane efflux protein through which antibiotic may be expelled.

###### 

Transmembrane regions of AcrA, AcrB, and TolC of the *Escherichia coli* isolates.

![](10.1177_1178636119889629-table6)

  Proteins   From   To    Length   Orientation
  ---------- ------ ----- -------- -------------
  AcrA       −      −     −        −
  AcrB       119    137   19       i-o
             145    163   19       o-i
             213    235   23       i-o
  TolC       114    138   25       o-i

Abbreviations: i-o, inner to outer; o-i, outer to inner.

Detection of mutation in AcrR {#section11-1178636119889629}
-----------------------------

The ARMS-PCR assay used 3 primers in a single PCR reaction tube. Two outside primers designed to amplify a common fragment of 805 bp flanking the mutation site served as an internal amplification control. The inner primer was specific for the mutation at position 133 of the gene and the amplicon was 530-bp long ([Figure 4A](#fig4-1178636119889629){ref-type="fig"}). The both amplicons were subjected to DNA sequencing and the result of sequencing confirmed the substitution of cytosine by thymine at position 133, which resulted a cysteine instead of an arginine at amino acid position 45 of AcrR ([Figure 4B](#fig4-1178636119889629){ref-type="fig"} and [C](#fig4-1178636119889629){ref-type="fig"}). The substitution of arginine to cysteine at position 45 of AcrR was observed only in the *E. coli* isolates that were assayed to have efflux pump ([Figure 2](#fig2-1178636119889629){ref-type="fig"}, [Tables 2](#table2-1178636119889629){ref-type="table"} and [4](#table4-1178636119889629){ref-type="table"}). However, no substitution of arginine to cysteine at position 45 of AcrR was observed in the *E. coli* isolates showing no EtBr fluorescence and no increased susceptibility to antibiotics in the presence of omeprazole. Similarly, this mutation was not observed in *AcrR* of *E. coli* ATCC 25922 that was susceptible to all antibiotics investigated.^[@bibr2-1178636119889629]^ These results suggested that the substitution of arginine to cysteine at position 45 of AcrR might be responsible for activation of the AcrAB-TolC efflux system.

![Agarose gel electrophoretogram and sequence output of ARMS PCR product for *AcrR*. All representative 5 isolates showed positive result for the presence of mutation (A). Normal *AcrR* has cytosine (B)^[@bibr19-1178636119889629]^ and mutant *AcrR* sequence has thymine (C) at position 133.\
L indicates the DNA ladder; ARMS PCR, amplification refractory mutation system polymerase chain reaction. *Escherichia coli* isolate numbers are indicated above the image of the gel with PCR products \~800 and 500 bp.](10.1177_1178636119889629-fig4){#fig4-1178636119889629}

Conclusions {#section12-1178636119889629}
===========

This study revealed that omeprazole increased the antibiotic susceptibility of the MDR *E. coli* isolates causing UTI in the North-East region of Bangladesh. AcrAB-TolC, one of the efflux pumps, has been partially characterized in the MDR *E coli* isolates, which might be important in future molecular docking study to predict and evaluate the inhibitor profiles of the AcrAB-TolC efflux pump. The efflux pump might be active only when substitution of arginine to cysteine occurs at position 45 of AcrR.

**Funding:**The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Declaration of conflicting interests:**The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Author contributions:** NC and SS equally contributed to experiments, data analysis, and preparing the draft manuscript. AP performed experiments for TolC. MKB and TR performed experiments for screening efflux pump and antibiotic susceptibility. MJA and KI participated in manuscript revision. AKA conceived and designed the experiments, analyzed and interpreted the data, and wrote the paper. All the authors have approved the final article.

**ORCID iDs:** Nandan Chowdhury ![](10.1177_1178636119889629-img1.jpg) <https://orcid.org/0000-0003-0723-0071>

Abul Kalam Azad ![](10.1177_1178636119889629-img1.jpg) <https://orcid.org/0000-0003-1918-3268>

[^1]: Shared first author.
